Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial
Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE
Archives of general psychiatry · 588 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Stanley Medical Research Institute
- Subvenciones
- Stanley Medical Research Institute (03T-315)
Según 1 financiador declarado.
Publicación
- Publicado
- 2010-02-01 · Arch Gen Psychiatry · vol. 67 · número 2 · pág. 146
- Editorial
- American Medical Association
- Citado
- 894 citas · más que el 100% de estudios similares · 80.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 45 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Fatty Acid Research and Health · Schizophrenia research and treatment · Bipolar Disorder and Treatment
- Palabras clave
- omega-3 polyunsaturated fatty acids, clinical high risk for psychosis, schizophrenia, adolescents and young adults, n-6/n-3 ratio, erythrocyte fatty acids, positive symptoms, negative symptoms, functional outcome, dietary supplementation, psychosis prevention, omega-3 deficiency
- MeSH
- humans, fatty acids, omega-3, treatment outcome, severity of illness index, risk factors, double-blind method, schizotypal personality disorder, psychotic disorders, health status, dose-response relationship, drug, diagnostic and statistical manual of mental disorders, adolescent, adult, patient acceptance of health care, female, male, young adult
9 autores
- G. Paul Amminger🇦🇹Medical University of Vienna
- Miriam R. Schäfer🇦🇹Medical University of Vienna
- Konstantinos G. Papageorgiou🇦🇹Medical University of Vienna
- Claudia M. Klier🇦🇺🇦🇹The University of Melbourne; Orygen; Medical University of Vienna
- Sue Cotton🇦🇺🇦🇹The University of Melbourne; Medical University of Vienna
- Susy Harrigan🇦🇺🇦🇹The University of Melbourne; Medical University of Vienna
- Andrew James Mackinnon🇦🇺🇦🇹The University of Melbourne; Medical University of Vienna
- Patrick D. McGorry🇦🇺🇦🇹The University of Melbourne; Medical University of Vienna
- Gregor Emanuel Berger🇦🇹Clienia AG; Medical University of Vienna
Resumen
El texto original del estudio, en el idioma en que se publicó.
Context
The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation.
Objective
To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis.
Design
Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007.
Setting
Psychosis detection unit of a large public hospital in Vienna, Austria.
Participants
Eighty-one individuals at ultra-high risk of psychotic disorder.
Interventions
A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months.
Main outcome measures
The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition.
Results
Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups.
Conclusions
Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states. Trial Registration clinicaltrials.gov Identifier: NCT00396643.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.